Global funding trends for malaria research in sub-Saharan Africa: a systematic analysis

Michael G Head, Sian Goss, Yann Gelister, Victor Alegana, Rebecca J Brown, Stuart C Clarke, Joseph R A Fitchett, Rifat Atun, J Anthony G Scott, Marie-Louise Newell, Sabu S Padmasad, Andrew J Tatem

Summary
Background Total domestic and international funding for malaria is inadequate to achieve WHO global targets in burden reduction by 2030. We describe the trends of investments in malaria-related research in sub-Saharan Africa and compare investment with national disease burden to identify areas of funding strength and potentially neglected populations. We also considered funding for malaria control.

Methods Research funding data related to malaria for 1997–2013 were sourced from existing datasets, from 13 major public and philanthropic global health funders, and from funding databases. Investments (reported in U$S) were considered by geographical area and compared with data on parasite prevalence and populations at risk in sub-Saharan Africa. 45 sub-Saharan African countries were ranked by amount of research funding received.

Findings We found 333 research awards totalling U$S814.4 million. Public health research covered $308.1 million (37·8%) and clinical trials covered $275.2 million (33.8%). Tanzania ($107.8 million [13·2%]), Uganda ($97.9 million [12·0%]), and Kenya ($92.9 million [11·4%]) received the highest sum of research investment and the most research awards. Malawi, Tanzania, and Uganda remained highly ranked after adjusting for national gross domestic product. Countries with a reasonably high malaria burden that received little research investment or funding for malaria control included Central African Republic (ranked 40th) and Sierra Leone (ranked 35th). Congo (Brazzaville) and Guinea had reasonably high malaria mortality, yet Congo (Brazzaville) ranked 38th and Guinea ranked 25th, thus receiving little investment.

Interpretation Some countries receive reasonably large investments in malaria-related research (Tanzania, Kenya, Uganda), whereas others receive little or no investments (Sierra Leone, Central African Republic). Research investments are typically highest in countries where funding for malaria control is also high. Investment strategies should consider more equitable research and operational investments across countries to include currently neglected and susceptible populations.

Funding Royal Society of Tropical Medicine and Hygiene and Bill & Melinda Gates Foundation.

Copyright © The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license.

Introduction
The current total domestic and international investments in malaria are considered grossly inadequate to meet the annual global target for investment of U$S6 billion. The 2015 Global Burden of Disease study estimated that there were 731 000 malaria-associated deaths (a decline of about 37% since 2005, along with a decline in age-standardised mortality of 43%) and 296 million positive cases (a decline of about 30% since 2005) in 2015, with a high prevalence in sub-Saharan Africa. To address this burden, malaria is the focus of large and well funded programmes from influential global health actors such as The Global Fund and the Bill & Melinda Gates Foundation, both of which have targeted malaria for elimination.

An estimated U$8.9 billion was disbursed globally for malaria control and elimination programmes between 2006 and 2010, with most of this funding targeted to Africa. As well as provision of finance from The Global Fund, substantial investment came from other actors, such as the World Bank and the President’s Malaria Initiative. As investment specifically focused on malaria control increases, the burden of malaria decreases, with interventions estimated to have averted 663 million clinical cases of malaria globally since 2000. Insecticide-treated nets, the most widespread intervention, were responsible for 68% of the averted cases. However, a substantial burden still remains, requiring efficient allocation of scarce financial resources to address gaps in implementation and research.

The ten largest global health research funders, which include the US National Institutes of Health, the European Commission, the Wellcome Trust, and the Bill & Melinda Gates Foundation, collectively invest about $37.1 billion into research each year, and malaria is a research priority or part of a wider focus (eg, global health) for these organisations. Investments cover the full pipeline of research, from preclinical science, to clinical trial phases and product development, and on to implementation and operational research. However, few multi-funder analyses of the focus of these awards exist.
The Research Investments in Global Health study (ResIn) has analysed funding trends in infectious disease research awarded to UK institutions and has identified Africa as being the focus of much of the UK global health research portfolio.\(^1\) Here, we aimed to systematically analyse investments in research related to malaria from founding international donors, in particular when the focus of the project was in sub-Saharan Africa. We also aimed to locate the site of the research at the national level, describe the geography of investment trends, and compare investments with the local prevalence of malaria caused by *Plasmodium falciparum* and malaria burden, as measured by the sizes of at-risk populations.

**Methods**

**Search strategy and selection criteria**

The process of collating and categorising infection-related research awards to UK institutions for this systematic analysis has been described in detail elsewhere.\(^1\) Briefly, we extracted award data for studies of infectious diseases from research related to malaria from leading international donors, in particular when the focus of the project was in sub-Saharan Africa. We also aimed to locate the site of the research at the national level, describe the geography of investment trends, and compare investments with the local prevalence of malaria caused by *Plasmodium falciparum* and malaria burden, as measured by the sizes of at-risk populations.

**Search strategy and selection criteria**

The process of collating and categorising infection-related research awards to UK institutions for this systematic analysis has been described in detail elsewhere.\(^1\) Briefly, we extracted award data for studies of infectious diseases from research related to malaria from leading international donors, in particular when the focus of the project was in sub-Saharan Africa. We also aimed to locate the site of the research at the national level, describe the geography of investment trends, and compare investments with the local prevalence of malaria caused by *Plasmodium falciparum* and malaria burden, as measured by the sizes of at-risk populations.

For more on UberResearch see http://www.uberresearch.com/dimensions-for-funders

For more on UberResearch see http://www.uberresearch.com/dimensions-for-funders

The study combined and then re-analysed open data sources from numerous key global health investors, and categorised the awards via the classification system developed by the ResIn study. This strategy allowed us to provide a comprehensive overview of the investment landscape, with actionable data that can help inform equitable decisions around resource allocation.

**Implications of all the available evidence**

The findings show that much of the available resources are directed towards key global health hubs in sub-Saharan Africa—for example, Tanzania, Uganda, and Kenya. However, several countries, such as Chad and Central African Republic, receive little or no research and operational funding despite having high malaria-associated burdens and mortality. These countries have neglected populations, and the global health community should reconsider strategies around resource allocation to reduce inequality and improve equity.
دریافت فوری متن کامل مقاله

امکان دانلود نسخه تمام متن مقالات انگلیسی
امکان دانلود نسخه ترجمه شده مقالات
پذیرش سفارش ترجمه تخصصی
امکان جستجو در آرشیو جامعی از صدها موضوع و هزاران مقاله
امکان دانلود رایگان ۲ صفحه اول هر مقاله
امکان پرداخت اینترنتی با کلیه کارت های عضو شتاب
دانلود فوری مقاله پس از پرداخت آنلاین
پشتیبانی کامل خرید با بهره مندی از سیستم هوشمند رهگیری سفارشات